देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
ANTI-D (RH) IMMUNOGLOBULIN (HUMAN)
KI BIOPHARMA LLC
J06BB01
ANTI-D (RH) IMMUNOGLOBULIN
2500UNIT
SOLUTION
ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) 2500UNIT
INTRAMUSCULAR
2.2ML
Schedule D
SERUMS
Active ingredient group (AIG) number: 0106269005; AHFS:
APPROVED
2022-06-27
KI BioPharma LLC Page 1 of 44 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION WINRHO ® SDF Rh o (D) Immunoglobulin (Human) for Injection Single-Dose Vials: 600 international units (120 mcg) 1,500 international units (300 mcg) 2,500 international units (500 mcg) 5,000 international units (1,000 mcg) 15,000 international units (3,000 mcg) World Health Organization (WHO) Anti-D Immunoglobulin (Human) 2 nd International Standard Passive Immunizing Agent KI BioPharma LLC 1209 Orange St. Wilmington, Delaware 19801 USA Distributor (in Canada): Accuristix 100 Vaughan Valley Blvd. Vaughan, Ontario L4H 3C5 Submission Control #: 264049 Date of Approval: June 27, 2022 KI BioPharma LLC Page 2 of 44 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................3 SUMMARY PRODUCT INFORMATION.................................................................... 3 DESCRIPTION ............................................................................................................ 3 INDICATIONS AND CLINICAL USE ......................................................................... 4 CONTRAINDICATIONS ............................................................................................. 5 WARNINGS AND PRECAUTIONS............................................................................. 6 ADVERSE REACTIONS ........................................................................................... 12 DRUG INTERACTIONS ............................................................................................ 17 DOSAGE AND ADMINISTRATION ......................................................................... 17 OVERDOSAGE ......................................................................................................... 20 ACTION AND CLINICAL PHARMACOLOGY ........................................................ 21 STORAGE AND STABILITY .................................................................................... 23 SPECIAL HANDLING INSTRUCTIONS....... पूरा दस्तावेज़ पढ़ें